BCIQ Profiles

Company Profile Report
0111 Mesoblast
BioCentury & Getty Images

Product Development

Mesoblast to seek advancement of heart failure cell therapy on 60% composite CV outcomes reduction

Jan 12, 2021 | 3:33 AM GMT

A composite analysis showing reductions in cardiac death, stroke and heart

Read the full 386 word article

How to gain access

Continue reading with a
two-week free trial.